Skip to main content
OLMA logo

OLMA · Olema Oncology, Inc. · Documents

Track OLMA — free
$7.02 -0.13 (-1.82%) At close · Nov 20 Play latest call Q4 2024 earnings call transcript
Market Cap
$615.00M
Shares
87.61M
Volume · Nov 20 1.26M Avg daily vol (3M) 1.27M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $162.45M 10-K filed Mar 16, 2026 Quarterly report FY2026 Q3 Net loss $73.6M 10-Q filed Nov 10, 2026 Latest results OPERA-01 top-line data on track for first quarter of 2027 8-K filed Nov 10, 2026 Earnings call Q4 2024 earnings call Held Mar 18, 2025
2026
Nov 18
Investor event
Palizestrant OPERO1 trial reads out in Q1

The CEO said the phase three OPERO1 monotherapy trial of palizestrant in the second, third-line setting reads out in Q1. Phase two data showed median PFS of 7.3 months in ESR1 mutant patients and 5.5 months in ESR1 wild-type patients. The trial assesses both ESR1 mutant and wild-type patients as individual endpoints.

4 source passages
OPERO1 is a monotherapy trial in the second, third-line setting, and that reads out in Q1. So in our phase two study, we saw about 7.3 months median PFS in the ESR1 mutant, 5.5 months in the ESR1 wild type. To assess these two patient populations as individual endpoints, so ESR1, PFS and ESR1 mutant, and PFS and ESR1 wild type. The lead is palizestrant. Open the document at this passage
Nov 12
Current report 8-K
Company changes name and relocates principal offices

Olema Oncology, Inc. changed its name from Olema Pharmaceuticals, Inc. effective November 12, 2026. It also relocated its principal executive offices to 365 Oyster Point Blvd., Suite 400, South San Francisco, California 94080.

Charter or bylaw amendment, or fiscal year change, Regulation FD disclosure, Other events Read from the first part of this long document
2 source passages
On November 12, 2026, Olema Oncology, Inc. (formerly known as Olema Pharmaceuticals, Inc.) (the “Company”) filed its Eighth Amended and Restated Certificate of Incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware to change the Company's corporate name from “Olema Pharmaceuticals, Inc.” to “Olema Oncology, Inc.” (the “Name Change”). The Restated Certificate became effective at 4:01 p.m., Eastern Time, on November 12, 2026. Effective November 12, 2026, the Company relocated its principal executive offices from 780 Brannan Street, San Francisco, CA 94103 to 365 Oyster Point Blvd., Suite 400, South San Francisco, CA 94080. Open the document at this passage
Nov 11
Investor event
Opera 01 readout slated for Q1 amid strong Opera 2 enrollment

Olima Oncology expects an Opera 01 readout in Q1, said Opera 2 is enrolling “extremely robustly,” and reported $414 million cash, with a possible mid-year 2028 launch.

5 source passages
Here we have Olima Oncology CEO, Sean. obviously in Q1 for OPRO one, the second line, second, third line study, we will have that readout. Opera 2, which is a first-line study with Kiskali, is enrolling extremely robustly. It does depend upon the readout, as you said, of course, of Opera 01. So those launch preparations are underway. earlier this week, did our Q2, $414 million cash at the end. We assume that we're going to be able to launch in 2028, maybe mid-year. Open the document at this passage
Nov 10
Investor event
Phase III topline expected in Q1 of next year

Olema expects Phase III topline results in Q1 of next year, including ESR-1 mutant and ESR-1 wild type subsets; cash on hand of about $414 million provides runway into 2028.

5 source passages
That compound is in two Phase III trials right now. And that trial reads out in... In Q1 of next year this is a very important piece of information for Olima specifically in the ESR-1 mutant and the ESR-1 wild type subsets Our cash on hand is about $414 million. That runway takes us nicely into 2028. Open the document at this passage
Nov 10
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Palazestrant OPERA-01 top-line results expected in 2027

Olema reported a $189.9 million net loss for the nine months ended September 30, 2026. Palazestrant’s Phase 3 OPERA-01 top-line results are expected in the first quarter of 2027, followed by an NDA submission in 2027.

Net loss $73.6M Diluted EPS -$0.73
Read from the MD&A section
2 source passages
Our net losses were $189.9 million and $116.4 million for the nine months ended September 30, 2026 and 2025, respectively. In November 2023, we initiated OPERA-01, our pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- MBC. We have completed enrollment and anticipate top-line results for this trial in the first quarter of 2027, expect to submit the new drug application (NDA) in 2027, and, if successful, anticipate potential U.S. Food and Drug Administration (FDA) approval and commercial launch in 2028. Open the document at this passage
Nov 10
Current report 8-K
OPERA-01 top-line data on track for first quarter of 2027

Olema Pharmaceuticals reported a $73.6 million net loss for the quarter ended September 30, 2026 and held $413.8 million in cash, cash equivalents, and marketable securities. It remains on track for OPERA-01 top-line data in the first quarter of 2027.

Financial results
3 source passages
On track to announce top-line data from the pivotal Phase 3 OPERA-01 trial in the first quarter of 2027 Net loss for the quarter ended September 30, 2026 was $73.6 million, as compared to $42.2 million for the quarter ended September 30, 2025. Cash, cash equivalents, and marketable securities as of September 30, 2026, were $413.8 million. Open the document at this passage
Oct 15
Current report 8-K Events of Oct 12
Director or officer change, or executive pay

Dr. Gorjan Hrustanovic resigned from Olema Pharmaceuticals, Inc.’s Board of Directors and two committees effective October 14, 2026, without any disagreement over operations, policies or practices; Dr. Prakash Raman joined both committees effective October 15, 2026.

Mar 16
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Net loss $162.45M Diluted EPS -$1.87
2025
Showing 1–50 of 122 documents
Key facts CIK 1750284 CUSIP 68062P106 13F (30d) 188 filings 170 filers Visit website Investor relations